VEGFA and type 2 diabetes mellitus: The VEGF‐A mRNA has been shown to improve cardiac function after myocardial infarction in preclinical models.[55, 56] Recently, naked VEGF‐A mRNA in a citrate saline solution (without LNPs as RNA carriers) was applied in clinical trials in patients with type 2 diabetes,[57] and patients undergoing coronary artery bypass grafting (CABG).[58, 59, 60] However, currently there is no known effective and safe carrier to deliver therapeutic VEGF‐A mRNA to the heart which could potentially stimulate VEGF‐A‐dependent blood vessel formation.